Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 8—August 2025

Research Letter

Seroprevalence of Rift Valley and Crimean-Congo Hemorrhagic Fever Viruses, Benin, 2022–2023

Nadine Olk, Anges Yadouleton, Olga Quenum, Stephane Sohou, Aime Goundote, Grace Aho Glele Rodrigue, Blaise Guezo-Mevo, Sonia Bedie, Michael Nagel, Petra Emmerich, Benjamin Hounkpatin, and Jan Felix DrexlerComments to Author 
Author affiliation: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin, Institute of Virology, Berlin, Germany (N. Olk, J.F. Drexler); Ecole Normale Supérieure de Natitingou, Université Nationale des Sciences, Technologies, Ingénierie et Mathématiques, Cotonou, Benin (A. Yadouleton); Laboratoire des Fièvres Hémorragiques Virales, Ministry of Health, Cotonou (A. Yadouleton, O. Quenum, S. Sohou, A. Goundote, G.A.G. Rodrique, B. Guezo-Mevo, S. Bedie, B. Hounkpatin); Deutsche Gesellschaft für Internationale Zusammenarbeit, Bonn, Germany (M. Nagel); Bernhard Nocht Institute of Tropical Medicine, Hamburg, Germany (P. Emmerich); Center of Internal Medicine, University Medicine Rostock, Rostock, Germany (P. Emmerich); German Centre for Infection Research, associated partner Charité-Universitätsmedizin, Berlin (J.F. Drexler)

Main Article

Figure 1

IFA for IgG against Rift Valley and Crimean-Congo hemorrhagic fever viruses, Benin, 2022–2023. A) Serum samples were tested using a commercial IFA (Euroimmun, https://www.euroimmun.com) with Rift Valley fever virus–infected Vero cells. Positive samples are shown at 1:100 dilution; white arrows mark infected cells. B) Serum samples were tested using in-house IFA with Crimean-Congo hemorrhagic fever virus–infected Vero cells (Appendix). Positive samples are shown at 1:10 dilution; white arrows mark infected cells. Titers are provided for the individual samples (Appendix Table). Noninfected controls are shown. Scale bars indicate 20 μm. +, positive serum sample; IFA, immunofluorescence assay.

Figure 1. IFA for IgG against Rift Valley and Crimean-Congo hemorrhagic fever viruses, Benin, 2022–2023. A) Serum samples were tested using a commercial IFA (Euroimmun, https://www.euroimmun.com) with Rift Valley fever virus–infected Vero cells. Positive samples are shown at 1:100 dilution; white arrows mark infected cells. B) Serum samples were tested using in-house IFA with Crimean-Congo hemorrhagic fever virus–infected Vero cells (Appendix). Positive samples are shown at 1:10 dilution; white arrows mark infected cells. Titers are provided for the individual samples (Appendix Table). Noninfected controls are shown. Scale bars indicate 20 μm. +, positive serum sample; IFA, immunofluorescence assay.

Main Article

Page created: June 23, 2025
Page updated: August 18, 2025
Page reviewed: August 18, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external